RU2015120645A - Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3) - Google Patents
Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3) Download PDFInfo
- Publication number
- RU2015120645A RU2015120645A RU2015120645A RU2015120645A RU2015120645A RU 2015120645 A RU2015120645 A RU 2015120645A RU 2015120645 A RU2015120645 A RU 2015120645A RU 2015120645 A RU2015120645 A RU 2015120645A RU 2015120645 A RU2015120645 A RU 2015120645A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- oligonucleotide
- fgfr3
- oligonucleotide according
- expression
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 4
- 210000002950 fibroblast Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 19
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 12
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 12
- 108020004999 messenger RNA Proteins 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 206010008723 Chondrodystrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 208000014884 cartilage development disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261729922P | 2012-11-26 | 2012-11-26 | |
| US61/729,922 | 2012-11-26 | ||
| PCT/EP2013/074552 WO2014080004A1 (en) | 2012-11-26 | 2013-11-25 | Compositions and methods for modulation of fgfr3 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015120645A true RU2015120645A (ru) | 2017-01-10 |
Family
ID=49639882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015120645A RU2015120645A (ru) | 2012-11-26 | 2013-11-25 | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9725723B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2922955B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6463687B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150088305A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104903448B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015012051A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2889993A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2922955T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015006289A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015120645A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014080004A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009323766B2 (en) | 2008-12-02 | 2016-10-06 | Wave Life Sciences Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
| SG177564A1 (en) | 2009-07-06 | 2012-02-28 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
| EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| WO2012068405A2 (en) | 2010-11-17 | 2012-05-24 | Isis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| SG10201912895PA (en) | 2012-07-13 | 2020-02-27 | Wave Life Sciences Ltd | Chiral control |
| JP6268157B2 (ja) | 2012-07-13 | 2018-01-24 | 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ | 不斉補助基 |
| BR112015012051A2 (pt) | 2012-11-26 | 2017-12-12 | Roche Innovation Ct Copenhagen As | composições e métodos para modulação de expressão de fgfr3 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
| JP7085985B2 (ja) | 2016-03-04 | 2022-06-17 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR102473372B1 (ko) | 2018-03-19 | 2022-12-05 | 다이호야쿠힌고교 가부시키가이샤 | 알킬황산나트륨을 포함하는 의약 조성물 |
| WO2021153703A1 (ja) * | 2020-01-31 | 2021-08-05 | 国立大学法人京都大学 | 軟骨形成異常症の治療 |
| WO2022211095A1 (ja) * | 2021-03-31 | 2022-10-06 | ルクサナバイオテク株式会社 | Ｆｇｆｒ３のアンチセンスオリゴヌクレオチド |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
| US4962029A (en) | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
| JPH08504559A (ja) | 1992-12-14 | 1996-05-14 | ハネウエル・インコーポレーテッド | 個別に制御される冗長巻線を有するモータシステム |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US20030087854A1 (en) * | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
| CN102180924A (zh) | 1999-05-04 | 2011-09-14 | 桑塔里斯制药公司 | L-核糖-lna类似物 |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| EP1562971B1 (en) | 2002-11-05 | 2014-02-12 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US8604183B2 (en) | 2002-11-05 | 2013-12-10 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| ATE442152T1 (de) | 2002-11-18 | 2009-09-15 | Santaris Pharma As | Antisense-entwurf |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| US7427672B2 (en) | 2003-08-28 | 2008-09-23 | Takeshi Imanishi | Artificial nucleic acids of n-o bond crosslinkage type |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| EP1964837A4 (en) * | 2005-11-22 | 2010-12-22 | Eisai R&D Man Co Ltd | Antitumor agent against multiple myeloma |
| CN102908630B (zh) | 2006-01-27 | 2014-11-19 | Isis制药公司 | 6-修饰的双环核酸类似物 |
| EP2015758B1 (en) | 2006-05-05 | 2014-04-02 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression apob |
| EP2066684B1 (en) | 2006-05-11 | 2012-07-18 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| CA2662978A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| MX2009002856A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Conjugados polimericos que contienen porciones cargadas positivamente. |
| EP2090127A2 (en) | 2006-10-30 | 2009-08-19 | Nokia Corporation | Method, apparatus and system providing operator controlled mobility for user equipment |
| US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
| ES2388590T3 (es) | 2007-05-30 | 2012-10-16 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido. |
| WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| WO2009006478A2 (en) | 2007-07-05 | 2009-01-08 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| PE20120553A1 (es) * | 2009-03-25 | 2012-05-18 | Genentech Inc | Anticuerpos anti-fgfr3 |
| WO2011139842A2 (en) * | 2010-04-28 | 2011-11-10 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| BR112015012051A2 (pt) | 2012-11-26 | 2017-12-12 | Roche Innovation Ct Copenhagen As | composições e métodos para modulação de expressão de fgfr3 |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2013
- 2013-11-25 BR BR112015012051A patent/BR112015012051A2/pt active Search and Examination
- 2013-11-25 DK DK13795243.8T patent/DK2922955T3/da active
- 2013-11-25 EP EP13795243.8A patent/EP2922955B1/en not_active Not-in-force
- 2013-11-25 US US14/647,430 patent/US9725723B2/en not_active Expired - Fee Related
- 2013-11-25 WO PCT/EP2013/074552 patent/WO2014080004A1/en not_active Ceased
- 2013-11-25 MX MX2015006289A patent/MX2015006289A/es unknown
- 2013-11-25 RU RU2015120645A patent/RU2015120645A/ru not_active Application Discontinuation
- 2013-11-25 CA CA2889993A patent/CA2889993A1/en not_active Abandoned
- 2013-11-25 CN CN201380061132.9A patent/CN104903448B/zh not_active Expired - Fee Related
- 2013-11-25 JP JP2015543449A patent/JP6463687B2/ja not_active Expired - Fee Related
- 2013-11-25 KR KR1020157016841A patent/KR20150088305A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015012051A2 (pt) | 2017-12-12 |
| MX2015006289A (es) | 2015-12-03 |
| DK2922955T3 (da) | 2019-05-13 |
| WO2014080004A1 (en) | 2014-05-30 |
| EP2922955A1 (en) | 2015-09-30 |
| CN104903448A (zh) | 2015-09-09 |
| EP2922955B1 (en) | 2019-03-06 |
| HK1208702A1 (en) | 2016-03-11 |
| KR20150088305A (ko) | 2015-07-31 |
| JP2016501520A (ja) | 2016-01-21 |
| CN104903448B (zh) | 2017-07-11 |
| US9725723B2 (en) | 2017-08-08 |
| US20150307886A1 (en) | 2015-10-29 |
| CA2889993A1 (en) | 2014-05-30 |
| JP6463687B2 (ja) | 2019-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015120645A (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3) | |
| TWI606059B (zh) | 反意義核酸 | |
| DK3118311T3 (en) | Antisense nucleic acid | |
| CN106661577B (zh) | 反义核酸 | |
| TWI725990B (zh) | 反義核酸 | |
| AU2017224226A1 (en) | Compositions and methods of using piRNAs in cancer diagnostics and therapeutics | |
| RU2018119315A (ru) | Олигонуклеотиды для индуцирования отцовской экспрессии ube3a | |
| CY1124197T1 (el) | Antinohmatika πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
| JP2010526797A5 (cg-RX-API-DMAC7.html) | ||
| JP2013510561A5 (cg-RX-API-DMAC7.html) | ||
| JP2010524486A5 (cg-RX-API-DMAC7.html) | ||
| KR20160104062A (ko) | 인공 핵산 분자 | |
| JP2023158214A (ja) | Ｈｉｆ２αの遺伝子発現を阻害する組成物及び方法 | |
| JP2008532477A5 (cg-RX-API-DMAC7.html) | ||
| TW200927176A (en) | RNA antagonist compounds for the modulation of PIK3CA expression | |
| JP2011524745A5 (cg-RX-API-DMAC7.html) | ||
| TW201016222A (en) | RNA antagonists targeting GLI2 | |
| CN113728102A (zh) | 使用剪接调节化合物进行新抗原工程化 | |
| KR20160098097A (ko) | 마이크로알앤에이 검출용 키트 및 방법 | |
| EP2175023A1 (en) | Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA | |
| JP2009502111A5 (cg-RX-API-DMAC7.html) | ||
| TW201102073A (en) | RNA antagonists targeting GLI2 for the treatment of leukemia | |
| WO2020007772A1 (en) | Antisense oligonucleotides targeting gbp-1 | |
| WO2020007889A1 (en) | Antisense oligonucleotides targeting stat1 | |
| HK40062073A (en) | Neoantigen engineering using splice modulating compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20181126 |